8 Amendments of Tiziana BEGHIN related to 2020/2071(INI)
Amendment 1 #
Draft opinion
Paragraph 1
Paragraph 1
1. Notes that the COVID-19 pandemic has revealed in the starkest possible terms the vital role played by functioning global supply chains for medical products, and in particular for medicines and treatments; emphasises that an open, transparent, rules-based trading system is fundamental to ensuring the global availability of medicines and guaranteeing an easy distribution and use;
Amendment 7 #
Draft opinion
Paragraph 1 a (new)
Paragraph 1 a (new)
1 a. Recalls the need to step up medicine production capacities in Europe ensuring the adequate availability of needed pharmaceuticals and limiting delivery bottlenecks;
Amendment 8 #
Draft opinion
Paragraph 1 b (new)
Paragraph 1 b (new)
1 b. Asks the Commission and Member States to allocate resources to support the reconversion of chemical plants in the EU for the production of active pharmaceutical ingredients in order to decrease dependency on third countries;
Amendment 10 #
Draft opinion
Paragraph 2
Paragraph 2
2. Recognises that the EUe lack of independence of medical products supply chains within the Union underlying the dependsency on a narrow set of countries for a large proportion of its imports of active pharmaceutical ingredients and chemical raw materials such as China and India; stresses that this over- reliance can pose a risk when limitations in production capacity, safety, excess demand or protectionist measures threaten the proper functioning of global supply chains and potentially undermine the availability of medicines in the EU; calls on the Commission to present a long-term strategy focused on ensuring the EU’s open strategic autonomy in health and reliable tools to check and increase the quality, safety, origin and compliance with the EU regulatory framework and avoid counterfeiting;
Amendment 29 #
Draft opinion
Paragraph 3
Paragraph 3
3. Emphasises that the EU is a leading global exporter of pharmaceutical products; notes that the protection and enforcement of IP rights in free trade agreements (FTAs) and at the WTO is crucial to the development of new medicines and treatments; underlines that the flexibilities provided in the TRIPS agreement can be used to address potential supply shortages in exceptional circumstances and solve the current problems related to the use of compulsory licencing;
Amendment 41 #
Draft opinion
Paragraph 4
Paragraph 4
4. Emphasises that a broad network of FTAs together with a functioning multilateral trading system constitute the best way of guaranteeing that multiple sources of manufacturing for essential medicines are available and easily checked against any counterfeiting in order to fully comply with regulatory standards convergein Europe and globally;
Amendment 49 #
Draft opinion
Paragraph 5
Paragraph 5
5. Strongly encourages all countries to join the WTO’s Pharmaceutical Tariff Elimination Agreement; calls for its scope to be extended to all pharmaceutical and medicinal products; stresses that medical products should be exempted from retaliation in trade disputes and easily accessible;
Amendment 63 #
Draft opinion
Paragraph 6
Paragraph 6
6. Underlines that a complete repatriation of medical supply chains is not possible in a global economy; urges the Commission and the Member States to work with the EU’s partners, the WHO and WTO, on establishing an international framework that can prevent the breakdown of supply chains and limit resort to protectionist measures during health crises especially considering the lack of EU medicine production facilities.